Wall Street brokerages expect that Allakos Inc (NASDAQ:ALLK) will report ($0.50) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Allakos’ earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.49). Allakos reported earnings of ($0.35) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 42.9%. The business is scheduled to report its next earnings results on Thursday, March 12th.
According to Zacks, analysts expect that Allakos will report full-year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.87). For the next financial year, analysts forecast that the company will report earnings of ($2.58) per share, with EPS estimates ranging from ($2.98) to ($2.17). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Allakos.
Allakos (NASDAQ:ALLK) last issued its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).
Shares of NASDAQ ALLK traded down $5.70 during mid-day trading on Tuesday, reaching $117.36. The company had a trading volume of 1,002,185 shares, compared to its average volume of 517,581. The stock has a fifty day moving average of $81.36 and a two-hundred day moving average of $65.20. Allakos has a 12-month low of $30.32 and a 12-month high of $139.99.
Several large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC purchased a new stake in shares of Allakos during the third quarter worth $42,000. Voya Investment Management LLC increased its position in Allakos by 14.4% in the 3rd quarter. Voya Investment Management LLC now owns 7,570 shares of the company’s stock worth $595,000 after purchasing an additional 952 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Allakos by 27.5% during the 2nd quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock worth $209,000 after purchasing an additional 1,040 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Allakos by 19.0% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 6,900 shares of the company’s stock worth $299,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its stake in shares of Allakos by 23.1% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 6,069 shares of the company’s stock worth $477,000 after purchasing an additional 1,138 shares in the last quarter. Institutional investors and hedge funds own 68.68% of the company’s stock.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Further Reading: How is diluted EPS different from basic EPS?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.